870100-86-0Relevant articles and documents
Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity
Falgueyret, Jean-Pierre,Desmarais, Sylvie,Oballa, Renata,Black, W. Cameron,Cromlish, Wanda,Khougaz, Karine,Lamontagne, Sonia,Massé, Frederic,Riendeau, Denis,Toulmond, Sylvie,Percival, M. David
, p. 7535 - 7543 (2005)
The lysosomal cysteine protease cathepsin K is a target for osteoporosis therapy. The arylpiperazine-containing cathepsin K inhibitor CRA-013783/L-006235 (1) displays greater than 4000-fold selectivity against the lysosomal/endosomal antitargets cathepsin